Andrew Bayliffe

Andrew Bayliffe is an experienced executive in the pharmaceutical sector, currently serving as Chief Development Officer at Quotient Therapeutics since September 2025. Previously, Bayliffe held the position of Chief Scientific Officer at Marengo Therapeutics from January 2020 to September 2025, and worked as a Venture Partner at Apple Tree Partners during the same timeframe. Bayliffe's extensive career at GSK spanned from June 2000 to January 2020, where roles included Head of the Respiratory and Inflammation Research Unit and Global Development Leader for Respiratory & Inflammation. Bayliffe began the career as a Research Scientist at AstraZeneca from October 1998 to June 2000. Academic credentials include a Doctor of Philosophy in Pharmacology and Molecular Biology from the University of Leeds and a Bachelor of Science in Pharmacology from The Manchester Metropolitan University.